Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 17130464
Nascimento EB, et al. (2006) Insulin-mediated phosphorylation of the proline-rich Akt substrate PRAS40 is impaired in insulin target tissues of high-fat diet-fed rats. Diabetes 55, 3221-8 17130464
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T642-p - AS160 (human)
Modsite: QFRRRAHtFSHPPSS SwissProt Entrez-Gene
Orthologous residues
AS160 (human): T642‑p, AS160 iso2 (human): T642‑p, AS160 iso3 (human): T642‑p, AS160 (mouse): T649‑p, AS160 iso2 (mouse): T649‑p, AS160 (rat): T651‑p, AS160 (cow): T644‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  diabetes mellitus, type 2 diabetes
Relevant cell lines - cell types - tissues:  'muscle, skeletal'
Cellular systems studied:  tissue
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase

T246-p - PRAS40 (human)
Modsite: LPRPRLNtSDFQKLK SwissProt Entrez-Gene
Orthologous residues
PRAS40 (human): T246‑p, PRAS40 iso2 (human): T116‑p, PRAS40 iso3 (human): T266‑p, PRAS40 (mouse): T247‑p, PRAS40 (rat): T247‑p, PRAS40 (cow): T246‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  diabetes mellitus, type 2 diabetes
Relevant cell lines - cell types - tissues:  'muscle, skeletal', 3T3 (fibroblast) [INSR (human)], 3T3-L1 (fibroblast), adipose tissue, H9c2 (myoblast), heart, liver
Cellular systems studied:  cell lines, tissue
Species studied:  human, mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
wortmannin insulin inhibit treatment-induced increase
LY294002 insulin inhibit treatment-induced increase
U0126 insulin no effect upon treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase

S473-p - Akt1 (mouse)
Modsite: RPHFPQFsYSASGTA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'muscle, skeletal', 3T3 (fibroblast) [INSR (human)], 3T3-L1 (fibroblast), adipose tissue, H9c2 (myoblast), heart, liver
Cellular systems studied:  tissue
Species studied:  mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
wortmannin insulin inhibit treatment-induced increase
LY294002 insulin inhibit treatment-induced increase
U0126 insulin no effect upon treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase
insulin increase
high-fat diet insulin inhibit treatment-induced increase
Associated Diseases
Diseases Alterations Comments
type 2 diabetes decreased using high fat diet-induced insulin resistance in mice as a model.

T649-p - AS160 (mouse)
Modsite: QFRRRAHtFSHPPSS SwissProt Entrez-Gene
Orthologous residues
AS160 (human): T642‑p, AS160 iso2 (human): T642‑p, AS160 iso3 (human): T642‑p, AS160 (mouse): T649‑p, AS160 iso2 (mouse): T649‑p, AS160 (rat): T651‑p, AS160 (cow): T644‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'muscle, skeletal', 3T3 (fibroblast) [INSR (human)], 3T3-L1 (fibroblast), adipose tissue, H9c2 (myoblast), heart, liver
Cellular systems studied:  tissue
Species studied:  mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
high-fat diet insulin inhibit treatment-induced increase
Associated Diseases
Diseases Alterations Comments
type 2 diabetes decreased using high fat diet-induced insulin resistance in mice as a model.

S21-p - GSK3A (mouse)
Modsite: SGRARTSsFAEPGGG SwissProt Entrez-Gene
Orthologous residues
GSK3A (human): S21‑p, GSK3A (mouse): S21‑p, GSK3A (rat): S21‑p, GSK3A (cow): S21‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'muscle, skeletal', adipose tissue, heart, liver
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
high-fat diet insulin inhibit treatment-induced increase
high-fat diet increase
Associated Diseases
Diseases Alterations Comments
type 2 diabetes decreased using high fat diet-induced insulin resistance in mice as a model.

S9-p - GSK3B (mouse)
Modsite: SGRPRTTsFAESCKP SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S9‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'muscle, skeletal', adipose tissue, heart, liver
Cellular systems studied:  tissue
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
high-fat diet insulin inhibit treatment-induced increase
high-fat diet increase
Associated Diseases
Diseases Alterations Comments
type 2 diabetes decreased using high fat diet-induced insulin resistance in mice as a model.

T247-p - PRAS40 (mouse)
Modsite: LPRPRLNtSDFQKLK SwissProt Entrez-Gene
Orthologous residues
PRAS40 (human): T246‑p, PRAS40 iso2 (human): T116‑p, PRAS40 iso3 (human): T266‑p, PRAS40 (mouse): T247‑p, PRAS40 (rat): T247‑p, PRAS40 (cow): T246‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  diabetes mellitus, type 2 diabetes
Relevant cell lines - cell types - tissues:  'muscle, skeletal', 3T3 (fibroblast) [INSR (human)], 3T3-L1 (fibroblast), adipose tissue, H9c2 (myoblast), heart, liver
Cellular systems studied:  cell lines, tissue
Species studied:  human, mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
wortmannin insulin inhibit treatment-induced increase
LY294002 insulin inhibit treatment-induced increase
U0126 insulin no effect upon treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase
insulin increase
high-fat diet insulin inhibit treatment-induced increase
Associated Diseases
Diseases Alterations Comments
type 2 diabetes decreased using high fat diet-induced insulin resistance in mice as a model.

S473-p - Akt1 (rat)
Modsite: RPHFPQFsYSASGTA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  'muscle, skeletal', 3T3 (fibroblast) [INSR (human)], 3T3-L1 (fibroblast), adipose tissue, H9c2 (myoblast), heart, liver
Cellular systems studied:  tissue
Species studied:  mouse, rat

T203-p - ERK1 (rat)
Modsite: HDHTGFLtEYVATRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  H9c2 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
U0126 insulin inhibit treatment-induced increase

Y205-p - ERK1 (rat)
Modsite: HTGFLTEyVATRWYR SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  H9c2 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
U0126 insulin inhibit treatment-induced increase

T183-p - ERK2 (rat)
Modsite: HDHTGFLtEYVATRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  H9c2 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
U0126 insulin inhibit treatment-induced increase

Y185-p - ERK2 (rat)
Modsite: HTGFLTEyVATRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  H9c2 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
U0126 insulin inhibit treatment-induced increase

T444-p - p70S6K (rat)
Modsite: RFIGSPRtPVSPVKF SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T444‑p, p70S6K iso2 (human): T421‑p, p70S6K (mouse): T444‑p, p70S6K (rat): T444‑p, p70S6K iso2 (rat): T421‑p, p70S6K (fruit fly): S429‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  H9c2 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin inhibit treatment-induced increase

S447-p - p70S6K (rat)
Modsite: GSPRTPVsPVKFSPG SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): S447‑p, p70S6K iso2 (human): S424‑p, p70S6K (mouse): S447‑p, p70S6K (rat): S447‑p, p70S6K iso2 (rat): S424‑p, p70S6K (fruit fly): S430‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  H9c2 (myoblast)
Cellular systems studied:  cell lines
Species studied:  rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
rapamycin insulin inhibit treatment-induced increase

T247-p - PRAS40 (rat)
Modsite: LPRPRLNtSDFQKLK SwissProt Entrez-Gene
Orthologous residues
PRAS40 (human): T246‑p, PRAS40 iso2 (human): T116‑p, PRAS40 iso3 (human): T266‑p, PRAS40 (mouse): T247‑p, PRAS40 (rat): T247‑p, PRAS40 (cow): T246‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  diabetes mellitus, type 2 diabetes
Relevant cell lines - cell types - tissues:  'muscle, skeletal', 3T3 (fibroblast) [INSR (human)], 3T3-L1 (fibroblast), adipose tissue, H9c2 (myoblast), heart, liver
Cellular systems studied:  cell lines, tissue
Species studied:  human, mouse, rat
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
insulin increase
wortmannin insulin inhibit treatment-induced increase
LY294002 insulin inhibit treatment-induced increase
U0126 insulin no effect upon treatment-induced increase
rapamycin insulin no effect upon treatment-induced increase